177 related articles for article (PubMed ID: 7679061)
21. A flow cytometric immunoassay to quantify adsorption of complement activation products (iC3b, C3d, SC5b-9) on artificial surfaces.
Gemmell CH
J Biomed Mater Res; 1997 Dec; 37(4):474-80. PubMed ID: 9407295
[TBL] [Abstract][Full Text] [Related]
22. Relative inefficiency of terminal complement activation.
Bhakdi S; Fassbender W; Hugo F; Carreno MP; Berstecher C; Malasit P; Kazatchkine MD
J Immunol; 1988 Nov; 141(9):3117-22. PubMed ID: 3262681
[TBL] [Abstract][Full Text] [Related]
23. Activation-dependent epitopes in the terminal complement pathway.
Mollnes TE; Lea T; Tschopp J
Complement Inflamm; 1989; 6(3):223-35. PubMed ID: 2472924
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical determination of complement activation in joint tissues of patients with rheumatoid arthritis and osteoarthritis using neoantigen-specific monoclonal antibodies.
Kemp PA; Spragg JH; Brown JC; Morgan BP; Gunn CA; Taylor PW
J Clin Lab Immunol; 1992; 37(4):147-62. PubMed ID: 1285067
[TBL] [Abstract][Full Text] [Related]
25. Glomerular deposition and urinary excretion of complement factor H in idiopathic membranous nephropathy.
Endo M; Fuke Y; Tamano M; Hidaka M; Ohsawa I; Fujita T; Ohi H
Nephron Clin Pract; 2004; 97(4):c147-53. PubMed ID: 15331938
[TBL] [Abstract][Full Text] [Related]
26. Increased plasma levels of the terminal complement complex in patients with evidence of complement activation.
Mollnes TE; Frøland SS; Harboe M
Complement; 1985; 2(2-3):175-84. PubMed ID: 3878765
[TBL] [Abstract][Full Text] [Related]
27. The role of the complement system in the pathogenesis of multiple organ failure in shock.
Zimmermann T; Laszik Z; Nagy S; Kaszaki J; Joo F
Prog Clin Biol Res; 1989; 308():291-7. PubMed ID: 2675054
[TBL] [Abstract][Full Text] [Related]
28. Anaphylatoxin and terminal complement complexes in red cell salvage.
Bengtsson A; Lisander B
Acta Anaesthesiol Scand; 1990 Jul; 34(5):339-41. PubMed ID: 2389647
[TBL] [Abstract][Full Text] [Related]
29. Blood dendritic cells carry terminal complement complexes on their cell surface as detected by newly developed neoepitope-specific monoclonal antibodies.
Würzner R; Xu H; Franzke A; Schulze M; Peters JH; Götze O
Immunology; 1991 Sep; 74(1):132-8. PubMed ID: 1718850
[TBL] [Abstract][Full Text] [Related]
30. Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation.
Rinder CS; Rinder HM; Smith BR; Fitch JC; Smith MJ; Tracey JB; Matis LA; Squinto SP; Rollins SA
J Clin Invest; 1995 Sep; 96(3):1564-72. PubMed ID: 7657827
[TBL] [Abstract][Full Text] [Related]
31. Complement Alternative Pathway׳s Activation in Patients With Lupus Nephritis.
Song D; Guo WY; Wang FM; Li YZ; Song Y; Yu F; Zhao MH
Am J Med Sci; 2017 Mar; 353(3):247-257. PubMed ID: 28262211
[TBL] [Abstract][Full Text] [Related]
32. Development and application of an enzyme-linked immunosorbent assay for the quantitation of alternative complement pathway activation in human serum.
Mayes JT; Schreiber RD; Cooper NR
J Clin Invest; 1984 Jan; 73(1):160-70. PubMed ID: 6418767
[TBL] [Abstract][Full Text] [Related]
33. Physiologic inactivation of fluid phase C3b: isolation and structural analysis of C3c, C3d,g (alpha 2D), and C3g.
Davis AE; Harrison RA; Lachmann PJ
J Immunol; 1984 Apr; 132(4):1960-6. PubMed ID: 6607952
[TBL] [Abstract][Full Text] [Related]
34. Terminal complement complex in septic shock with capillary leakage: marker of complement activation?
Schuerholz T; Leuwer M; Cobas-Meyer M; Vangerow B; Kube F; Kirschfink M; Marx G
Eur J Anaesthesiol; 2005 Jul; 22(7):541-7. PubMed ID: 16045145
[TBL] [Abstract][Full Text] [Related]
35. Characterization of C3 in C3 glomerulopathy.
Sethi S; Vrana JA; Fervenza FC; Theis JD; Sethi A; Kurtin PJ; Zhang Y; Smith RJH
Nephrol Dial Transplant; 2017 Mar; 32(3):459-465. PubMed ID: 27507892
[TBL] [Abstract][Full Text] [Related]
36. Monoclonal antibodies against complement 3 neoantigens for detection of immune complexes and complement activation. Relationship between immune complex levels, state of C3, and numbers of receptors for C3b.
Aguado MT; Lambris JD; Tsokos GC; Burger R; Bitter-Suermann D; Tamerius JD; Dixon FJ; Theofilopoulos AN
J Clin Invest; 1985 Oct; 76(4):1418-26. PubMed ID: 2932466
[TBL] [Abstract][Full Text] [Related]
37. Effects on complement activation and cytokine (TNF-alpha and IL-8) release of infusion of anti-TNF-antibodies or a xanthine derivative (HWA 138) in septic baboons.
Bengtsson A; Redl H; Schlag G; Mollnes TE; Högåsen K
Acta Anaesthesiol Scand; 1996 Feb; 40(2):244-9. PubMed ID: 8848926
[TBL] [Abstract][Full Text] [Related]
38. Studies on the mechanism of bacterial resistance to complement-mediated killing. VI. IgG increases the bactericidal efficiency of C5b-9 for E. coli 0111B4 by acting at a step before C5 cleavage.
Joiner KA; Goldman RC; Hammer CH; Leive L; Frank MM
J Immunol; 1983 Nov; 131(5):2570-5. PubMed ID: 6355297
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of C5a-induced inflammation with preserved C5b-9-mediated bactericidal activity in a human whole blood model of meningococcal sepsis.
Sprong T; Brandtzaeg P; Fung M; Pharo AM; Høiby EA; Michaelsen TE; Aase A; van der Meer JW; van Deuren M; Mollnes TE
Blood; 2003 Nov; 102(10):3702-10. PubMed ID: 12881318
[TBL] [Abstract][Full Text] [Related]
40. Roller and centrifugal pumps compared in vitro with regard to haemolysis, granulocyte and complement activation.
Moen O; Fosse E; Bråten J; Andersson C; Fagerhol MK; Venge P; Høgåsen K; Mollnes TE
Perfusion; 1994 Mar; 9(2):109-17. PubMed ID: 7919596
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
